2 completed, 1 active not recruiting, 1 not yet recruiting. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
Follow Dendreon: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer Sipuleucel-T, N803 - Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-11-30 | 2026-08-10 |
| Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer Sipuleucel-T - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | Active not recruiting | University of Oklahoma | 15 | 2023-11-12 | 2026-05-27 |
| Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer Atezolizumab1200 mg IV, Sipuleucel-T - Prostate Cancer Metastatic | Phase 1 | Completed | University of Hawaii | 37 | 2017-02-06 | 2021-05-26 |
| Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors EC D-3263 HCl - Solid Tumors | Phase 1 | Completed | Dendreon | 23 | 2009-03-01 | 2012-05-02 |
sipuleucel-T (3) · ALT-803 (1)
United States (4)
Jared Acoba, MD (1) · Kelly Stratton, MD (1) · Russell K Pachynski, M.D. (1)